



Doherty, D. J., Sykes, R., Connelly, P. J. and Hood, S. (2022) ST-elevation myocardial infarction due to coronary thrombus in a young patient with diabetic ketoacidosis and a new diagnosis of type-2 diabetes. *BMJ Case Reports*, (Accepted for Publication).

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<https://eprints.gla.ac.uk/264973/>

Deposited on: 9 February 2022

Enlighten – Research publications by members of the University of Glasgow
<https://eprints.gla.ac.uk>

1 **ST-elevation myocardial infarction due to coronary thrombus in the context**
2 **of diabetic ketoacidosis in a young patient with a new diagnosis of type-2**
3 **diabetes**

4 **Keywords**

5 Acute coronary syndrome, percutaneous coronary intervention, intracoronary imaging,
6 diabetes mellitus, case report

7 **Authors**

8 Daniel J Doherty¹ MBChB BSc, Robert Sykes^{1,2} MBChB BMSc, Paul J Connelly² MBChB
9 BMSc, Stuart Hood¹ MD

10 **Affiliations**

- 11 1. West of Scotland Regional Heart and Lung Centre, Golden Jubilee National Hospital,
12 Glasgow, UK
13 2. British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of
14 Cardiovascular and Medical Sciences, University of Glasgow, UK

15 **Short title**

16 Thrombotic STEMI as first presentation of diabetes

17 **Word count:** 849

18 **Corresponding author**

19 Dr Daniel Doherty, West of Scotland Regional Heart and Lung Centre, Golden Jubilee
20 National Hospital, Glasgow, G81 4DY, UK. Email: Daniel.Doherty@glasgow.ac.uk. Tel:
21 +447568601540.

22 **Summary**

23 The association between cardiovascular disease and diabetes is increasingly understood and
24 shared therapeutic targets are emerging. We describe the presentation and successful
25 management of STEMI secondary to coronary thrombus in a young patient with a new
26 diagnosis of type 2 diabetes and diabetic ketoacidosis (DKA).

27 **Background**

28 This case emphasises the importance of considering aetiology of myocardial infarction other
29 than coronary atherosclerotic plaque rupture, particularly in young patients presenting with
30 acute coronary syndrome. The cardiovascular sequelae of severe metabolic derangement can
31 be life threatening and DKA should be considered in the context of acute illness with metabolic
32 acidosis.

33 **Case presentation**

34 A 24-year-old male was admitted as an emergency via the ambulance service to our regional
35 cardiology centre with a view to percutaneous coronary intervention (PCI). He presented with
36 chest pain on a background of schizophrenia, intermittent alcohol excess, cigarette smoking,
37 obesity (BMI 32kg/m²) and a family history of premature cardiovascular disease, his mother
38 having died of an acute myocardial infarction in her 40's. The patient denied illicit drug use
39 and there was no documented history of this. Regular prescribed medication were olanzapine
40 15mg once daily and fluoxetine 80mg once daily and had been established for over a year.

41 Symptoms included a 24-hour history of vomiting and diarrhoea following excess alcohol
42 consumption and a six-hour history of severe central chest pain radiating to his left arm with
43 associated autonomic symptoms. There was no polyuria or excessive thirst and weight had
44 been stable.

45 On arrival the patient was in discomfort, diaphoretic and tachycardic with a heart rate of
46 110bpm. Initial blood pressure was 134/86mmHg and there was no subsequent haemodynamic
47 compromise. On physical examination, lungs were clear to auscultation and heart sounds were
48 normal with no cardiac murmur or gallop. Jugular venous pressure was not elevated and there
49 was no peripheral oedema. The abdomen was soft and non-tender to palpation throughout with
50 no organomegaly.

51 12-lead electrocardiogram (ECG) demonstrated ST-segment elevation in leads II, III and AVF
52 with reciprocal ST-segment depression in lead I and AVL (*Figure 1*). Emergency coronary
53 angiography performed 12-minutes following the ECG in *Figure 1* demonstrated preserved

54 flow (TIMI – “Thrombolysis in Myocardial Infarction” Grade III) in the right coronary artery
55 (RCA) but occlusion of the distal posterior left ventricular (PLV) branch. Coronary
56 intravascular ultrasound (IVUS) identified thrombus burden throughout the RCA but did *not*
57 demonstrate atherosclerotic plaque rupture (*Figure 2*). The left coronary system was normal in
58 appearance. Following coronary intervention chest pain resolved. However, the patient
59 remained tachycardic and diaphoretic.

60 **Investigations and differential diagnosis**

61 Routine laboratory investigations revealed hyperglycaemia (blood glucose 20.4mmol/L), a
62 raised anion gap metabolic acidosis (lactate 10.9mmol/L, bicarbonate 15mmol/L) and
63 ketonuria (3+) in keeping with DKA. Liver enzymes were mildly elevated in the context of
64 recent alcohol excess. White blood cell count was elevated at 25.9 (109/l) with neutrophilia
65 and C-reactive protein (CRP) was normal. High sensitivity troponin T was elevated at 1212
66 ng/L and total serum cholesterol was 6.2mmol/L with LDL 3.9mmol/L. Prothrombin time and
67 partial thromboplastin time were normal. Thrombophilia screen was not undertaken as results
68 would be influenced by acute thrombosis and anticoagulant therapy. Complete admission
69 laboratory results are presented in *Table 1*.

70 Transthoracic echocardiography demonstrated impaired left ventricular systolic function
71 (estimated left ventricular ejection fraction 49%) with inferior wall hypokinesis. There was no
72 evidence of atrial or ventricular septal defect, and no evidence of intracardiac thrombus.
73 The primary diagnosis was inferior STEMI in the context of a new diagnosis of diabetes
74 complicated by DKA. Significant lactataemia contributed to a mixed acidosis picture
75 secondary to tissue hypoperfusion in the setting of acute cardiac ischaemia and catecholamine
76 surge. Clinical examination and investigations did not support systemic infection or sepsis
77 syndrome. Specifically, chest radiograph was normal, CRP <1mg/L and nasopharyngeal swab
78 polymerase chain reaction testing for SARS-CoV-2 was negative. Further investigations were
79 undertaken to clarify the underlying metabolic diagnosis. Glycosylated haemoglobin (HBA1c)
80 was 64mmol/mol. C-peptide level was elevated at 996pmol/L with concomitant random serum
81 glucose of 12.6 mmol/L suggesting significant endogenous insulin production and insulin
82 resistance. Both glutamic acid decarboxylase antibodies (Anti-GAD) and islet antigen 2
83 antibodies (Anti- IA2) were undetectable. Consensus opinion on the underlying metabolic
84 diagnosis considering the patient’s body habitus and absence of autoimmunity is type 2
85 diabetes. Ketoacidosis in the setting of type 2 diabetes is uncommon and recent alcohol excess

86 is likely to have led to an enhanced state of physiological stress and contributed to metabolic
 87 decompensation [1].

88

Haematology	
White Blood Cells	25.9 (10 ⁹ /l)
Red Blood Cells	4.7 (10 ¹² /l)
Haemoglobin	158 g/L
Haematocrit	0.4 l/l
Mean Cell Volume	92.9 fl
Platelets	352 (10 ⁹ /l)
Neutrophils	22.4 (10 ⁹ /l)
Renal function and electrolytes	
Sodium	134 mmol/L
Potassium	3.2 mmol/L
Chloride	94 mmol/L
Bicarbonate	15 mmol/L
Urea	1.2 mmol/L
Creatinine	76 umol/L
Estimated Glomerular Filtration Rate	>60 ml/min
Liver function	
Bilirubin	9 umol/L
Aspartate Aminotransferase	74 IU/L
Alanine Aminotransferase	152 IU/L
Gamma-Glutamyl Transferase	145 IU/L
Bone profile	
Adjusted Calcium	2.2 mmol/L
Phosphate	1.2 mmol/L
Magnesium	0.59 mmol/L
Albumin	43 g/L
Alkaline Phosphatase	99 IU/L
Lipid profile	
Cholesterol	6.2 mmol/L
Triglyceride	3.1 mmol/L
High-Density Lipoprotein	0.9 mmol/L
Low-Density Lipoprotein	3.9 mmol/L
Cholesterol/HDL	7
Other	
Lactate	10.9 mmol/L
High Sensitivity Troponin T	1212 ng/L
Serum Osmolality	290 mOsm/kg

Table 1 – Admission laboratory test results

89

90 Treatment

91 Acute coronary syndrome was treated with oral antiplatelet agents and intravenous
 92 unfractionated heparin and morphine in a pre-hospital setting. This was followed by emergency
 93 primary PCI using low pressure balloon angioplasty to the occluded PLV branch, then
 94 aspiration thrombectomy yielding large amounts of macroscopic red thrombus from the RCA.
 95 Persisting intracoronary thrombus was confirmed on IVUS following coronary intervention
 96 and intravenous glycoprotein IIb/IIIa inhibitor was subsequently administered. Secondary

97 prevention medications including ACE-inhibitor, beta-blocker and statin were initiated.
98 Previous case reports have highlighted recurrent STEMI in the setting of type 2 diabetes, DKA
99 and coronary artery thrombus and we advised a three-month treatment period with dual
100 antiplatelet therapy [2].

101 DKA was treated with intravenous fluids, variable rate intravenous insulin infusion and
102 electrolyte replacement. Metabolic disturbance resolved quickly; within six hours of
103 presentation blood glucose had reduced to 10mmol/L and lactate to 3.1mmol/L. By 15 hours,
104 acid base status had normalised, ketonuria resolved and minimal doses (0-0.5 units/hr) of
105 intravenous insulin were needed to maintain blood glucose levels within normal range. Insulin
106 was discontinued after 24-hours. Following specialist review, metformin and dapagliflozin
107 were initiated as oral hypoglycaemic agents.

108 **Outcome and follow-up**

109 ST-segment changes persisted for approximately 24 hours following PCI, likely related to
110 distal thrombus embolization. 12-lead ECG three days following initial presentation
111 demonstrated inferior Q waves and T- wave inversion (*Figure 3*). Blood glucose levels
112 remained within normal range on oral hypoglycaemic agents without ketonuria. The patient
113 was discharged from hospital after four days. Through lifestyle measures he has achieved 6kg
114 of weight loss and HBA1c has reduced to 51mmol/mol. There is outpatient follow-up in place
115 with cardiology, cardiac rehabilitation including smoking cessation counselling and specialist
116 diabetes clinical teams.

117 **Discussion**

118 The association between diabetes and cardiovascular disease is well recognised. Underpinning
119 pathophysiological processes include vascular endothelial dysfunction, accelerated
120 atherosclerosis, increased platelet activation and impaired fibrinolysis leading to a
121 prothrombotic state [3,4]. In a large population-based cohort study in patients with STEMI,
122 diabetes was associated with a 72% excess risk of death [5]. DKA further promotes a
123 prothrombotic state with increased von Willebrand factor and decreased free protein S and
124 protein C activity [6]. Arterial thrombosis in this setting has been recognised for over 50 years
125 [7].

126 Symptom chronology in this case suggests that metabolic disturbance was followed by
127 myocardial ischaemia. Combined with evidence of *thrombotic* coronary occlusion in otherwise
128 normal coronary arteries in a 24-year-old patient we believe that DKA was responsible for the

129 acute coronary syndrome (ACS). Myocardial infarction due to a primary coronary
130 atherosclerotic event can also precipitate DKA and our patient had multiple risk factors for
131 atherosclerosis including a family history of premature cardiovascular disease, cigarette
132 smoking, obesity, dyslipidaemia, and type-2 diabetes of uncertain duration. However,
133 intracoronary imaging did not identify plaque rupture and metabolic decompensation following
134 a cardiac event typically occurs in individuals with established type-1 diabetes. A temporal
135 illustration of the possible underlying physiological mechanisms in this case is presented in
136 *Figure 4*.

137 Shared therapeutic pathways between diabetes and cardiovascular disease continue to emerge.
138 Dapagliflozin is a potent and reversible, selective sodium-glucose cotransporter-2 inhibitor
139 (SGLT2i) which reduced the rate of hospitalization for heart failure and cardiovascular death
140 relative to placebo in patients with multiple risk factors for cardiovascular disease. SGLT2
141 inhibitors whilst designed as oral hypoglycaemic agents, are advantageous in cardiovascular
142 secondary prevention therapy, reducing major adverse cardiovascular events, heart failure
143 admissions and progression of renal disease [8].

144 **Learning points/take home messages**

- 145 • Aetiology of myocardial infarction other than coronary atherosclerotic plaque rupture
146 should be considered in young patient groups presenting with acute coronary syndrome.
- 147 • Cardiovascular sequelae of severe metabolic derangement can be life threatening.
- 148 • Acute coronary syndrome and other physiological stressors such as excess alcohol
149 consumption can lead to metabolic decompensation in susceptible individuals.
150 Recognition of cardiac risk factors in these patients is important.
- 151 • DKA should be a differential diagnosis in the context of acute illness with metabolic
152 acidosis regardless of previously established endocrine pathology.
- 153 • Emerging shared therapeutic pathways in cardiovascular and endocrine disease provide
154 the opportunity for individualised treatment approaches, and underline the benefits of
155 collaborative, cross-speciality care.

156 **References**

- 157 1. Barski L, Nevzorov R, Jotkowitz A, Rabaev E, Zektser M, Zeller L, et al. Comparison of
158 Diabetic Ketoacidosis in Patients With Type-1 and Type-2 Diabetes Mellitus. *Am J Med Sci*.
159 2013;345(4):326–30.
- 160 2. Sharma AM, Wilks J. Recurrent Coronary Artery Thrombus Formation in the Setting of

161 Diabetic Ketoacidosis. J Invasive Cardiol. 2011;23:E1–4.
162 3. Matheus AS de M, Tannus LRM, Cobas RA, Palma CCS, Negrato CA, Gomes M de B.
163 Impact of Diabetes on Cardiovascular Disease: An Update. Int J Hypertens. 2013;2013:1–15.
164 4. Carr ME. Diabetes mellitus A hypercoagulable state. J Diabetes Complications.
165 2001;(15):44–54.
166 5. Alabas OA, Hall M, Dondo TB, Rutherford MJ, Timmis AD, Batin PD, et al. Long-term
167 excess mortality associated with diabetes following acute myocardial infarction: a population-
168 based cohort study. J Epidemiol Community Health. 2017;71(1):25–32.
169 6. Carl GF, Hoffman WH, Passmore GG, Truemper EJ, Lightsey AL, Cornwell PE, et al.
170 Diabetic Ketoacidosis Promotes a Prothrombotic State. Endocr Res. 2003;29(1):73–82.
171 7. FitzGerald MG, O’Sullivan DJ, Malins JM. Fatal Diabetic Ketosis. BMJ. 1961;1(5221):247–
172 50.
173 8. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors
174 for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes:
175 a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet.
176 2019;393(10166):31–9.

177 **Figures**

178 *Figure 1* - 12-lead ECG at presentation demonstrating inferior STEMI
179 *Figure 2* - A) Angiographic appearance of thrombus in proximal RCA and reduced flow in
180 PLV branch. B) Coronary thrombosis confirmed on IVUS in proximal RCA
181 *Figure 3* - 12-lead ECG three-days following presentation demonstrating inferior Q-waves and
182 T-wave inversion
183 *Figure 4* - Temporal illustration of possible mechanisms of myocardial infarction and DKA


184 **Patient’s perspective**

185 “I phoned an ambulance because I had chest pain. I was told by the ambulance crew that I was
186 having a heart attack, so I was rushed to hospital where I had an emergency procedure. After
187 that I was taken to the ward and started on tablets and drip medications. It was explained that
188 I had diabetes and would need some new medications. After a couple of days, I started to feel
189 better.”


190

191 *Figure 1 - 12-lead ECG at presentation demonstrating inferior STEMI*


192



193 *Figure 2 - A) Angiographic appearance of thrombus in proximal RCA and reduced flow in PLV branch. B) Coronary thrombosis confirmed on*
194 *IVUS in proximal RCA*



195 *Figure 3 - 12-lead ECG three-days following presentation demonstrating inferior Q-waves and T-wave*



196 *Figure 4 - Temporal illustration of possible mechanisms of myocardial infarction and DKA*

197

